2015 American Transplant Congress
Donor Specific Tolerance Can Be Induced by Donor Bone Marrow Transfer With Activation of Invariant Naturel Killer T Cells
It has been reported that liposomal formulation of a-galactosylceramide(lipo-aGC) could induce antigen specific regulatory T cells (Treg) in vivo when administered with particular antigens. We…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Non-Cytoreductive Immunosuppression Prevents Rejection of Vascularized Composite Allografts
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss such as an extremity or face. Immunosuppression-free donor-specific immunological tolerance has been successfully…2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
1University of Maryland School of Medicine, Baltimore; 2Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
1Surgery, Emory University, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…2015 American Transplant Congress
Eomes-Expressing CD8+ T Cells and Th17 Cells Mediate Costimulatory Blockade-Resistant Allograft Rejection in Mice
The etiology of costimulatory blockade-resistant allograft rejection remains unclear. Therefore, the purpose of this study was to evaluate the responsiveness of distinct CD4+ and CD8+…2015 American Transplant Congress
Tissue Engineering Human Kidneys for Costimulation Blockade
1BREONICS, Inc., Watervliet, NY; 2Surgery, University of Utrecht, Utrecht, Netherlands.
Methods for preserving organs have employed hypothermic conditions. At these temperatures metabolism is 4% of normal. Tissue engineering of organs cannot be done without significant…2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
1Duke University, Durham, NC; 2Emory University, Atlanta, GA; 3Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…
American Transplant Congress abstracts